Rituximab Export Market Intelligence: India's 164 Suppliers Shipping to 104 Countries — TransData Nexus 2026

Q: Who are the top rituximab exporters from India?

The top rituximab exporters from India are: 1. DR.REDDY'S LABORATORIES LTD — $7.9M (41.5% market share); 2. RELIANCE LIFE SCIENCES PRIVATE LIMITED — $4.1M (21.4% market share); 3. DR REDDYS LABORATORIES LIMITED — $2.6M (13.8% market share); 4. MEDWISE OVERSEAS PRIVATE LIMITED — $1.1M (5.7% market share); 5. HETERO BIOPHARMA LIMITED — $901.0K (4.7% market share). Together they account for 87.1% of India's total rituximab export value.

Q: What is the total export value of rituximab from India?

The total export value of rituximab from India is $19.1M USD, recorded across 1,215 shipment transactions from 164 active exporters to 104 destination countries. The average shipment value is $15.7K.

Q: Which countries import rituximab from India?

India exports rituximab to 104 countries worldwide. The top importing countries are: RUSSIA (47.2% share, $9.0M), SRI LANKA (11.3% share, $2.2M), COLOMBIA (6.1% share, $1.2M), VENEZUELA (5.7% share, $1.1M), MEXICO (3.8% share, $719.8K). These five markets account for 74.1% of total export value.

Q: What is the HS code for rituximab exports from India?

The primary HS code for rituximab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of rituximab exports from India?

The average unit price for rituximab exports from India is $104.42 USD per unit, with prices ranging from $0.01 to $2534.33 depending on formulation, packaging, and order volume. The total market is valued at $19.1M across 1,215 shipments.

Q: Which ports handle rituximab exports from India?

The primary ports for rituximab exports from India are SAHAR AIR (32.0% of shipments), SAHAR AIR CARGO ACC (INBOM4) (26.7% of shipments), Bombay Air (7.0% of shipments), Bombay Air Cargo (4.8% of shipments), HYDERABAD ACC (INHYD4) (3.8% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of rituximab?

India is one of the world's leading exporters of rituximab due to its large base of 164 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports rituximab to 104 countries, demonstrating 53% global market coverage.

Q: What certifications do Indian rituximab exporters need?

Indian rituximab exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import rituximab from India?

There are 292 registered buyers importing rituximab from India, spread across 104 countries. The repeat buyer rate is 53.8%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top rituximab supplier from India?

DR.REDDY'S LABORATORIES LTD is the leading rituximab exporter from India with a market share of 41.5% and total export value of $7.9M across 64 shipments. The top 5 suppliers together control 87.1% of total export value.

Suresh Sormare

Rituximab

India Pharmaceutical Trade Intelligence

$19.1M164 Suppliers104 CountriesHS 30021500

ExportsIndia → RUSSIA47.2%India → SRI LANKA11.3%

ImportsGERMANY → India$4.0M SWITZERLAND → India$487.9K

#1 Buyer: JSC R-PHARM

Rituximab Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Rituximab to the World

Between 2022 and 2026, India exported $19.1M worth of rituximab across 1,215 verified shipments to 104 countries — covering 53% of world markets in the Advanced Oncology segment. The largest destination is RUSSIA (47.2%). DR.REDDY'S LABORATORIES LTD leads with a 41.5% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Rituximab export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Rituximab export data snapshot — $19.1M · 164 exporters · 104 countriesTransData Nexus · Indian Customs Data

Top Rituximab Exporters from India

164 active exporters · Ranked by export value

View all 164 →

Top Rituximab Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	DR.REDDY'S LABORATORIES LTD	$7.9M	64	17	41.5%
2	RELIANCE LIFE SCIENCES PRIVATE LIMITED

Top Countries Importing Rituximab from India

104 destination markets · Ranked by import value

All 104 countries →

Top Countries Importing Rituximab from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	RUSSIA	$9.0M	47.2%
2	SRI LANKA	$2.2M	11.3%
3	COLOMBIA	$1.2M	6.1%
4	VENEZUELA	$1.1M	5.7%
5	MEXICO	$719.8K	3.8%
6	KENYA	$657.9K	3.4%
7	PHILIPPINES	$383.0K	2.0%
8	PERU	$371.3K	1.9%
9	UNITED STATES	$350.9K	1.8%
10	BANGLADESH	$271.1K	1.4%

RUSSIA is India's largest rituximab export destination, absorbing 47.2% of total exports worth $9.0M. The top 5 importing countries — RUSSIA, SRI LANKA, COLOMBIA, VENEZUELA, MEXICO — together account for 74.1% of India's total rituximab export value. The remaining 99 destination countries collectively receive the other 25.9%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Rituximab to India?

9 origin countries · Total import value: $4.7M

India imports rituximab from 9 countries with a combined import value of $4.7M. The largest supplier is GERMANY ($4.0M, 23 shipments), followed by SWITZERLAND and UNITED KINGDOM. All values are from Indian Customs (DGFT) import records.

Countries Supplying Rituximab to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$4.0M	23	85.8%
2	SWITZERLAND	$487.9K	4	10.5%
3	UNITED KINGDOM	$108.3K	2	2.3%
4	SOUTH KOREA	$28.6K	4	0.6%
5	SINGAPORE	$18.5K	2	0.4%
6	UNITED STATES	$15.6K	18	0.3%
7	NETHERLANDS	$3.3K	1	0.1%
8	TAIWAN	$2.2K	2	0.0%
9	SOUTH AFRICA	$36	8	0.0%

GERMANY is the largest supplier of rituximab to India, accounting for 85.8% of total import value. The top 5 origin countries — GERMANY, SWITZERLAND, UNITED KINGDOM, SOUTH KOREA, SINGAPORE — together supply 99.5% of India's rituximab imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Rituximab

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, rituximab is approved under the brand name Rituxan for indications such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. The FDA's Orange Book lists several approved Abbreviated New Drug Applications (ANDAs) for rituximab biosimilars, reflecting a competitive market landscape. For instance, on September 27, 2019, the FDA approved Rituxan for the treatment of adult and pediatric patients aged 2 years and older with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA). This approval granted exclusivity until September 27, 2026. Given the substantial number of Indian exporters (164) and the competitive pricing, Indian manufacturers are well-positioned to meet the demand for rituximab in the U.S. market.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) has authorized several rituximab biosimilars. For example, Ituxredi received marketing authorization on September 19, 2024, for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. (ema.europa.eu) However, some products have been withdrawn; Ritemvia's marketing authorization was withdrawn on June 22, 2021, at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring compliance with Good Manufacturing Practice (GMP) guidelines for manufacturing and quality control.

3WHO Essential Medicines & Global Standards

Rituximab is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The WHO Prequalification Programme evaluates rituximab products to ensure they meet international standards for quality, safety, and efficacy. Compliance with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) is essential for market acceptance and regulatory approval.

4India Regulatory Classification

In India, rituximab is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing; for instance, a ceiling price was established in March 2025 to ensure affordability. Exporting rituximab requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of export activities.

5Patent & Exclusivity Status

The primary patents for rituximab have expired, leading to increased generic competition and the introduction of biosimilars in various markets. This competitive environment has contributed to the diversification of suppliers and more accessible pricing, benefiting healthcare systems globally.

6Recent Industry Developments

In June 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a new indication for Imbruvica in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma eligible for autologous stem cell transplantation. (ema.europa.eu) Additionally, in July 2023, rituximab received orphan designation from the EMA for the treatment of primary membranous nephropathy, highlighting ongoing research into new therapeutic applications. (ema.europa.eu) These developments reflect the dynamic nature of the rituximab market and the continuous efforts to expand its therapeutic indications.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Rituximab

Retail & reference prices across 9 markets vs. India FOB export price of $104.42/unit

Global Price Benchmark for Rituximab across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	Data not available	USD	Specific pricing information for Rituximab in the United States is not readily available from public government sources.
United Kingdom	Data not available	GBP	The UK's NHS Drug Tariff does not list Rituximab pricing publicly.
Germany	Data not available	EUR	German public health insurance systems negotiate drug prices, but specific figures for Rituximab are not publicly disclosed.
Australia	Data not available

Supply Chain Risk Assessment — Rituximab

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Rituximab, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian pharmaceutical manufacturing are sourced from China, with KSM dependency even higher. This reliance poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical production capabilities. For instance, environmental regulations and factory shutdowns in China have previously led to shortages and price volatility in API supplies.

Recognizing this vulnerability, the Indian government has initiated measures to reduce dependence on Chinese imports. In October 2024, under the Production Linked Incentive (PLI) scheme, two greenfield plants were inaugurated to manufacture critical molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are essential for antibiotic production. These efforts aim to bolster domestic API production and mitigate supply chain risks associated with external dependencies.

2Supplier Concentration & Single-Source Risk

The export market for Rituximab from India is highly concentrated, with the top five exporters accounting for 87.1% of the total export value. Notably, DR. REDDY'S LABORATORIES LTD alone holds a 41.5% share. Such concentration poses a single-source risk; any operational disruptions within these key companies could significantly impact global supply.

Access Complete Rituximab Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 1,215 transactions across 104 markets.

Request Demo View Pricing

Frequently Asked Questions — Rituximab Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top rituximab exporters from India?

The leading rituximab exporters from India are DR.REDDY'S LABORATORIES LTD, RELIANCE LIFE SCIENCES PRIVATE LIMITED, DR REDDYS LABORATORIES LIMITED, and 11 others. DR.REDDY'S LABORATORIES LTD leads with 41.5% market share ($7.9M). The top 5 suppliers together control 87.1% of total export value.

What is the total export value of rituximab from India?

The total export value of rituximab from India is $19.1M, recorded across 1,215 shipments from 164 active exporters to 104 countries. The average shipment value is $15.7K.

Which countries import rituximab from India?

India exports rituximab to 104 countries. The top importing countries are RUSSIA (47.2%), SRI LANKA (11.3%), COLOMBIA (6.1%), VENEZUELA (5.7%), MEXICO (3.8%), which together account for 74.1% of total export value.

What is the HS code for rituximab exports from India?

The primary HS code for rituximab exports from India is 30021500. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Rituximab

Rituximab

Top Rituximab Exporters from India

Top Countries Importing Rituximab from India

Who Supplies Rituximab to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Rituximab

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Rituximab

Supply Chain Risk Assessment — Rituximab

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Rituximab Trade Intelligence

Frequently Asked Questions — Rituximab Exports from India

Who are the top rituximab exporters from India?

What is the total export value of rituximab from India?

Which countries import rituximab from India?

What is the HS code for rituximab exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of rituximab exports from India?

Which ports handle rituximab exports from India?

Why is India a leading exporter of rituximab?

What certifications do Indian rituximab exporters need?

How many buyers import rituximab from India?

What is the market share of the top rituximab exporter from India?

Analysis Methodology